



Patent  
Office




INVESTOR IN PEOPLE

GB00/01725 09/980971

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

*W. Evans*

Dated

- 7 AUG 2000

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference P23782/CMC/GWO

2. Patent application number  
(The Patent Office will fill in this part)

6 MAY 1999

9910323.6

3. Full name, address and postcode of the or of each applicant (underline all surnames)

University of Ulster  
Faculty of Engineering  
Newtownabbey  
County Antrim, BT37 0QB

Patents ADP number (if you know it)

5905918004

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

"Cardiac Defibrillation"

5. Name of your agent (if you have one)

Murgitroyd & Company

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

373 Scotland Street  
Glasgow  
G5 8QA

Patents ADP number (if you know it)

1198013

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	-
Description	6
Claim(s)	-
Abstract	-
Drawing(s)	2 + 2

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (Patents Form 7/77) -

Request for preliminary examination and search (Patents Form 9/77) -

Request for substantive examination (Patents Form 10/77) -

Any other documents (please specify) -

11.

I/We request the grant of a patent on the basis of this application.

Signature   
MURGITROYD & COMPANY

Date 5.5.1999

12. Name and daytime telephone number of person to contact in the United Kingdom

Graham Wotherspoon 0141 307 8400

### Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.

## 1     Cardiac Defibrillation

---

2

3     This invention relates to cardiac defibrillation, and  
4     ~~in particular (but not exclusively) to an apparatus for~~  
5     delivering an electrical defibrillating signal to a  
6     human heart in the state of atrial fibrillation (AF),  
7     using transdermal energy transfer to a passive  
8     implanted device.

9

10    Atrial fibrillation is a common heart arrhythmia that  
11    increases in prevalence with age, with typically 10% of  
12    people over the age of 70 experiencing an incident.  
13    The process of cardioversion of AF to normal sinus  
14    rhythm (SR) has traditionally been attempted by  
15    pharmacological measures or transthoracic direct  
16    current shock. The former has been limited by variable  
17    cardioversion rates and the risk of side effects, in  
18    particular proarrhythmia. The latter requires sedation  
19    or anaesthesia and high energy shocks, and there is a  
20    high recurrence rate. For these reasons, there has  
21    been interest in catheter-based transvenous atrial  
22    defibrillation and its potential use in an implantable  
23    atrial defibrillator. However, atrial implantable  
24    defibrillators are complex devices requiring on-board  
25    pattern recognition with complex recording and follow-

1 up procedures. The need for electrical charging  
2 circuitry using active devices adds to the complexity  
3 and weight of the implant.

4  
5 The present invention provides an apparatus for cardiac  
6 defibrillation which comprises an external circuit and  
7 an implantable circuit; the external circuit including  
8 an induction transmitting coil and signal generating  
9 means for applying radio frequency pulses of  
10 predetermined shape to the transmitting coil; the  
11 implantable circuit including an induction receiving  
12 coil for receiving pulses when the two coils are in  
13 proximity, and a rectification circuit having an input  
14 connected to the receiving coil and an output driving  
15 electrodes implantable in the heart.

16  
17 In a preferred form of the invention, for use in atrial  
18 defibrillation, the power transmitted per pulse is less  
19 than about 5J and the radio frequency is in the range  
20 3-30 MHz, typically about 7MHz.

21  
22 The signal generating means suitably comprises a radio  
23 frequency generator switched or gated under the control  
24 of a pulse generation and shaping means which in turn  
25 is responsive to an ecg synchronisation signal. The  
26 ecg synchronisation signal may be provided via a  
27 telemetry transmitter implanted in the patient.

28  
29 The external circuit may further include a telephony  
30 link by which the ecg may be transmitted to, and/or the  
31 apparatus controlled from, a remote location.

32  
33 The external and implantable circuits preferably  
34 include impedance matching components, typically  
35 capacitors, to achieve a high degree of tuning.

36

1 The inductive coupling will typically be tuned to  
2 resonance, preferably by use of series resonance in the  
3 external circuit and parallel resonance in the  
4 implantable circuit.

5

6 Most preferably, the implantable circuit contains only  
7 passive components.

8

9 From another aspect the invention provides a method of  
10 cardiac (preferably atrial) defibrillation which  
11 comprises transmitting pulses of controlled shape and  
12 energy transdermally by high frequency magnetic  
13 induction to a substantially passive implanted circuit  
14 which includes electrodes implanted in the heart.

15

16 It is known to transfer energy transdermally by  
17 induction, but only for purposes of recharging  
18 batteries in implanted devices such as pacemakers or  
19 continuously powering implanted devices such as pumps.  
20 It has not hitherto been proposed to use such  
21 techniques to transfer controlled waveforms for high-  
22 energy physiological stimulation.

23

24 An embodiment of the invention will now be described,  
25 by way of example, with reference to the accompanying  
26 drawings, in which:

27

28 Figure 1 shows the elements required for controlled,  
29 transdermal energy delivery to a cardiac load;  
30 Figure 2 illustrates the circuitry required external to  
31 the body; and  
32 Figure 3 represents the body-internal circuitry.

33

34 In the apparatus (Figure 1), an appropriately  
35 synchronised trigger pulse is firstly generated, based  
36 on the subject's electrocardiogram (ecg). This pulse,

1 after shaping to a waveform 1 suitable for AF  
2 conversion, is used to amplitude modulate a radio  
3 frequency (RF) carrier generator 2 at a power level  
4 consistent with the transmission of 1-5 J of energy to  
5 the internal load, itself nominally 50  $\Omega$  resistive.  
6 The transmission path takes the form of a pair of  
7 coaxially-aligned transmit 3 and receive 4 inductors  
8 constructed in the form of an RF transformer. The  
9 diameters of the coils 3 and 4 are set so as to  
10 optimise energy transfer at a physical spacing not less  
11 than the thoracic wall's thickness. Both inductors are  
12 wound with enamelled copper wire. The transmitting  
13 coil 3 is mounted on an insulated paddle to facilitate  
14 adjustment in its placement on the subject's body. The  
15 implanted circuitry is mounted on a printed circuit  
16 board and consists of the receiving coil 4 connected to  
17 impedance matching, rectification and wave-shaping  
18 components 5. The final defibrillating signal is  
19 connected to the heart 6 by catheters 7, one placed in  
20 the lateral right atrium (RA) and the other in the  
21 distal great cardiac vein via the coronary sinus.  
22 Alternatively, any conventional atrial defibrillation  
23 delivery system may be used.

24

25 In one example, the coils 3 and 4 are designed to give  
26 optimum inductive coupling at a centre-to-centre  
27 spacing of 20mm. Given a maximum diameter of for  
28 practicability the receiving coil 4 of 35mm, the  
29 transmitting coil 3 has a diameter of 53mm. Both  
30 inductors are wound with 1.5mm enamelled copper wire.  
31 The transmitting coil 3 is arranged as a solenoidal  
32 coil, spaced at one turn. The receiving coil 4 is  
33 pile-wound to conserve space in the final implant.

34

35 Both inductors in the apparatus are tuned to resonance  
36 at the selected operating frequency of the system,

1 typically in the range 3-30 MHz. The transmitter uses  
2 series tuning by capacitor 9 (Figure 2), whilst the  
3 receiving coil 4 is parallel-tuned, with capacitive  
4 matching to the load 10 (Figure 3), by means of  
5 capacitors C1 and C2. A radio-frequency choke 11  
6 provides a DC path for rectifier current.

7  
8 Pulse widths will typically be in the range 6-60ms.  
9 Single pulses are usually applied in a clinical  
10 situation.

11

---

12 Optionally, as shown in Figure 1 a telemetry link 8 may  
13 be incorporated to provide ecg monitoring and feedback-  
14 derived, automatic tuning of the energy delivery  
15 system. Such a link may also be powered from energy  
16 delivered transdermally, by using a low-power transfer  
17 to power up the telemetry link, or to charge an on-  
18 board battery. Alternatively, the ecg could be  
19 transmitted via the induction coils using a suspended  
20 carrier technique.

21

22 As is also indicated in Figure 1, the external  
23 circuitry may include a remote communication link,  
24 which may be via telephone communication (landline or  
25 GSM) or via a radio link. This would, for example,  
26 enable the patient's ecg to be transmitted to a  
27 hospital for monitoring and for inspection by a  
28 physician. Defibrillation could be activated remotely,  
29 and spoken instructions could be conveyed to the  
30 patient.

31

32 Atrial defibrillation currently requires a pulse energy  
33 of about 3 to 4J. By using a tuned inductive coupling  
34 as described, typically at a frequency about 7 MHz,  
35 these energy levels can be transmitted transdermally  
36 while maintaining control of pulse shape and timing.



1 It is contemplated that by refining the pulse shape,  
2 duration and timing required to achieve defibrillation  
3 the energy necessary could be reduced to 1J or less,  
4 which would be painless to the patient and remove any  
5 need for sedation.

6  
7 The pulse form shown in Figure 1 is a biphasic pulse,  
8 which is the form we currently prefer. However, other  
9 pulse forms and hence RF envelope shapes may also be  
10 used, such as monophasic and multiple.

---

11  
12 Although described above with particular reference to  
13 atrial defibrillation, the invention could find use in  
14 ventricular defibrillation. Here, though, the required  
15 energy levels are much higher (typically about 15J).

16  
17 It will be appreciated that one of the benefits of the  
18 embodiment described is that the implanted hardware is  
19 entirely passive and does not require any implanted  
20 power source. However, the invention does not exclude  
21 the possibility of some active components being  
22 implanted, with a reduced requirement for an internal  
23 source of power.

24  
25 Other modifications may be made within the scope of the  
26 present invention.

1/2




Fig.1.



2/2




Fig. 2.




Fig. 3.